RT Journal Article
T1 Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
A1 Guasch, Montserrat
A1 Cañete, Fiorella
A1 Ordas, Ingrid
A1 Iglesias-Flores, Eva
A1 Clos, Ariadna
A1 Gisbert, Javier P
A1 Taxonera, Carlos
A1 Vera, Isabel
A1 Minguez, Miguel
A1 Guardiola, Jordi
A1 Rivero, Montserrat
A1 Nos, Pilar
A1 Gomollon, Fernando
A1 Barrio, Jesus
A1 de Francisco, Ruth
A1 Lopez-Sanroman, Antonio
A1 Martin-Arranz, M Dolores
A1 Garcia-Planella, Esther
A1 Camargo, Raquel
A1 Garcia-Lopez, Santiago
A1 de Castro, Luisa
A1 Calvet, Xavier
A1 Esteve, Maria
A1 Mañosa, Míriam
A1 Domenech, Eugeni
K1 Anti-TNF
K1 Immunosuppressants
K1 Inflammatory bowel disease
K1 Surgery
AB Biological therapies may be changing the natural history of inflammatory bowel diseases (IBDs), reducing the need for surgical intervention. We aimed to assess whether the availability of anti-TNF agents impacts the need for early surgery in Crohn's disease (CD) and ulcerative colitis (UC). Retrospective, cohort study of patients diagnosed within a 6-year period before and after the licensing of anti-TNFs (1990-1995 and 2007-2012 for CD; 1995-2000 and 2007-2012 for UC) were identified in the ENEIDA Registry. Surgery-free survival curves were compared between cohorts. A total of 7370 CD patients (2022 in Cohort 1 and 5348 in Cohort 2) and 8069 UC patients (2938 in Cohort 1 and 5131 in Cohort 2) were included. Immunosuppressants were used significantly earlier and more frequently in both CD and UC post-biological cohorts. The cumulative probability of surgery was lower in CD following anti-TNF approval (16% and 11%, 22% and 16%, and 29% and 19%, at 1, 3, and 5 years, respectively P  Anti-TNF availability was associated with a reduction in early surgery for CD (driven mainly by earlier and more widespread immunosuppressant use) but not in UC.
PB Elsevier
YR 2020
FD 2020-12-07
LK http://hdl.handle.net/10668/15469
UL http://hdl.handle.net/10668/15469
LA en
NO Guasch M, Cañete F, Ordás I, Iglesias-Flores E, Clos A, Gisbert JP, et al. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. J Gastroenterol Hepatol. 2020 Dec;35(12):2080-2087
DS RISalud
RD Aug 8, 2025